| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S G Siris, P C Bermanzohn, S E Mason, A Rifkin, J M Alvi. Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse. Progress in neuro-psychopharmacology & biological psychiatry. vol 16. issue 4. 1992-08-31. PMID:1641497. |
twenty-one schizophrenic or schizoaffective patients with histories of cannabis abuse and operationally-defined syndromes of post-psychotic depression completed a double-blind trial of adjunctive imipramine added to their on-going medication regimen of fluphenazine decanoate and benztropine. |
1992-08-31 |
2023-08-11 |
Not clear |
| K T Mueser, P R Yarnold, A S Bellac. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta psychiatrica Scandinavica. vol 85. issue 1. 1992-04-10. PMID:1546548. |
the relationship between history of specific types of substance abuse (alcohol, stimulants, cannabis, hallucinogens, narcotics) and demographic and diagnostic variables was evaluated in a large (n = 263) sample of schizophrenic, schizoaffective, major depression and bipolar disorder patients. |
1992-04-10 |
2023-08-11 |
Not clear |
| P E Greenbaum, M E Prange, R M Friedman, S E Silve. Substance abuse prevalence and comorbidity with other psychiatric disorders among adolescents with severe emotional disturbances. Journal of the American Academy of Child and Adolescent Psychiatry. vol 30. issue 4. 1991-10-17. PMID:1890091. |
significant factors (p less than 0.05) associated with severe alcohol or marijuana abuse/dependency diagnosis included (1) residential mental health treatment program, 2.37 odds ratio (or); (2) conduct disorder diagnosis, 2.18 or; (3) depression diagnosis, 1.75 or; (4) states, 1.43 or; (5) age, 1.29 or; and (6) a depression x facility interaction, 1.91 or. |
1991-10-17 |
2023-08-11 |
Not clear |
| L M Koran, I F Lit. House staff well-being. The Western journal of medicine. vol 148. issue 1. 1988-03-10. PMID:3341147. |
in all, 40% reported that anxiety or depression impaired their performance for a month or more; 12% reported an increased use of alcohol, marijuana, or cocaine; and 7% an increased use of sedatives, stimulants, or opioids. |
1988-03-10 |
2023-08-11 |
Not clear |
| S A Turkanis, R Karle. Central excitatory properties of delta 9-tetrahydrocannabinol and its metabolites in iron-induced epileptic rats. Neuropharmacology. vol 21. issue 1. 1982-05-27. PMID:6278353. |
furthermore, pretreatment with cannabidiol markedly altered the responses to delta 9-thc in the following ways: focal depression was partially blocked, polyspike activity was enhanced and convulsions abolished. |
1982-05-27 |
2023-08-12 |
rat |
| S A Turkanis, R Karle. Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology. vol 75. issue 3. 1982-03-13. PMID:6275447. |
in contrast, cannabidiol, over a wide dosage range, caused only depression. |
1982-03-13 |
2023-08-12 |
rat |
| S A Turkanis, P Chiu, H K Borys, R Karle. Influence of delta9-tetrahydrocannabinol and cannabidiol on photically evoked after-discharge potentials. Psychopharmacology. vol 52. issue 2. 1977-09-22. PMID:407606. |
in anticonvulsant doses, trimethadione and ethosuximide produced an extensive depression of after-discharge activity, whereas diphenylhydantoin and cannabidiol exerted no such effect. |
1977-09-22 |
2023-08-11 |
rat |
| J W Bellville, J C Gasser, T Miyake, K Aqle. Tolerance to the respiratory effects of marijuana in man. The Journal of pharmacology and experimental therapeutics. vol 197. issue 2. 1976-08-02. PMID:1271283. |
there was a significant change from base-line controls, indicating respiratory depression following marijuana smoking. |
1976-08-02 |
2023-08-11 |
human |